🇺🇸 FDA
Patent

US 12102637

Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

granted A61KA61K31/513A61K9/1611

Quick answer

US patent 12102637 (Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis) held by Neurocrine Biosciences, Inc. expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/513, A61K9/1611, A61K9/1623, A61K9/1652